1opj

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
(New page: 200px<br /><applet load="1opj" size="450" color="white" frame="true" align="right" spinBox="true" caption="1opj, resolution 1.75&Aring;" /> '''Structural basis for...)
Line 1: Line 1:
-
[[Image:1opj.gif|left|200px]]<br /><applet load="1opj" size="450" color="white" frame="true" align="right" spinBox="true"
+
[[Image:1opj.gif|left|200px]]<br /><applet load="1opj" size="350" color="white" frame="true" align="right" spinBox="true"
caption="1opj, resolution 1.75&Aring;" />
caption="1opj, resolution 1.75&Aring;" />
'''Structural basis for the auto-inhibition of c-Abl tyrosine kinase'''<br />
'''Structural basis for the auto-inhibition of c-Abl tyrosine kinase'''<br />
==Overview==
==Overview==
-
c-Abl is normally regulated by an autoinhibitory mechanism, the disruption, of which leads to chronic myelogenous leukemia. The details of this, mechanism have been elusive because c-Abl lacks a phosphotyrosine residue, that triggers the assembly of the autoinhibited form of the closely, related Src kinases by internally engaging the SH2 domain. Crystal, structures of c-Abl show that the N-terminal myristoyl modification of, c-Abl 1b binds to the kinase domain and induces conformational changes, that allow the SH2 and SH3 domains to dock onto it. Autoinhibited c-Abl, forms an assembly that is strikingly similar to that of inactive Src, kinases but with specific differences that explain the differential, ability of the drug STI-571/Gleevec/imatinib (STI-571) to inhibit the, catalytic activity of Abl, but not that of c-Src.
+
c-Abl is normally regulated by an autoinhibitory mechanism, the disruption of which leads to chronic myelogenous leukemia. The details of this mechanism have been elusive because c-Abl lacks a phosphotyrosine residue that triggers the assembly of the autoinhibited form of the closely related Src kinases by internally engaging the SH2 domain. Crystal structures of c-Abl show that the N-terminal myristoyl modification of c-Abl 1b binds to the kinase domain and induces conformational changes that allow the SH2 and SH3 domains to dock onto it. Autoinhibited c-Abl forms an assembly that is strikingly similar to that of inactive Src kinases but with specific differences that explain the differential ability of the drug STI-571/Gleevec/imatinib (STI-571) to inhibit the catalytic activity of Abl, but not that of c-Src.
==About this Structure==
==About this Structure==
-
1OPJ is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Mus_musculus Mus musculus] with CL, MYR and STI as [http://en.wikipedia.org/wiki/ligands ligands]. Active as [http://en.wikipedia.org/wiki/Transferase Transferase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.10.1 and 2.7.10.2 2.7.10.1 and 2.7.10.2] Full crystallographic information is available from [http://ispc.weizmann.ac.il/oca-bin/ocashort?id=1OPJ OCA].
+
1OPJ is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Mus_musculus Mus musculus] with <scene name='pdbligand=CL:'>CL</scene>, <scene name='pdbligand=MYR:'>MYR</scene> and <scene name='pdbligand=STI:'>STI</scene> as [http://en.wikipedia.org/wiki/ligands ligands]. Active as [http://en.wikipedia.org/wiki/Transferase Transferase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.10.1 and 2.7.10.2 2.7.10.1 and 2.7.10.2] Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1OPJ OCA].
==Reference==
==Reference==
Line 22: Line 22:
[[Category: Superti-Furga, G.]]
[[Category: Superti-Furga, G.]]
[[Category: Veach, D.]]
[[Category: Veach, D.]]
-
[[Category: Young, M.A.]]
+
[[Category: Young, M A.]]
[[Category: CL]]
[[Category: CL]]
[[Category: MYR]]
[[Category: MYR]]
Line 28: Line 28:
[[Category: transferase]]
[[Category: transferase]]
-
''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Tue Nov 20 23:05:16 2007''
+
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 14:20:11 2008''

Revision as of 12:20, 21 February 2008


1opj, resolution 1.75Å

Drag the structure with the mouse to rotate

Structural basis for the auto-inhibition of c-Abl tyrosine kinase

Overview

c-Abl is normally regulated by an autoinhibitory mechanism, the disruption of which leads to chronic myelogenous leukemia. The details of this mechanism have been elusive because c-Abl lacks a phosphotyrosine residue that triggers the assembly of the autoinhibited form of the closely related Src kinases by internally engaging the SH2 domain. Crystal structures of c-Abl show that the N-terminal myristoyl modification of c-Abl 1b binds to the kinase domain and induces conformational changes that allow the SH2 and SH3 domains to dock onto it. Autoinhibited c-Abl forms an assembly that is strikingly similar to that of inactive Src kinases but with specific differences that explain the differential ability of the drug STI-571/Gleevec/imatinib (STI-571) to inhibit the catalytic activity of Abl, but not that of c-Src.

About this Structure

1OPJ is a Single protein structure of sequence from Mus musculus with , and as ligands. Active as Transferase, with EC number and 2.7.10.2 2.7.10.1 and 2.7.10.2 Full crystallographic information is available from OCA.

Reference

Structural basis for the autoinhibition of c-Abl tyrosine kinase., Nagar B, Hantschel O, Young MA, Scheffzek K, Veach D, Bornmann W, Clarkson B, Superti-Furga G, Kuriyan J, Cell. 2003 Mar 21;112(6):859-71. PMID:12654251

Page seeded by OCA on Thu Feb 21 14:20:11 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools